AI Analysis | Feedback

A smaller Johnson & Johnson, focusing on dermatology and diverse drug development.

A biotech incubator that also sells dermatology drugs.

A miniature Pfizer, but with an even broader and more varied drug pipeline.

AI Analysis | Feedback

• Ximino capsules: Treats inflammatory lesions of non-nodular moderate to severe acne vulgaris.
• Targadox: Used for severe acne.
• Exelderm cream: Addresses ringworm and and jock itch symptoms.
• Ceracade: Formulated for dry skin conditions.
• Luxamend: Used for dressing and managing wounds.
• Accutane capsules: Treats severe recalcitrant nodular acne.
• Intravenous Tramadol: A late-stage product candidate for the treatment of post-operative acute pain.
• CUTX-101: An injection, a late-stage candidate for the treatment of Menkes disease.
• MB-107 and MB-207: Late-stage candidates for the treatment of X-linked severe combined immunodeficiency.
• Cosibelimab: A late-stage product candidate for metastatic cancers.
• CK-101: A late-stage candidate for the treatment of patients with EGFR mutation-positive NSCLC.
• CAEL-101: A late-stage product candidate for the treatment of amyloid light chain amyloidosis.
• Triplex vaccine: A late-stage vaccine candidate for cytomegalovirus.
• CEVA101: A late-stage candidate for the treatment of severe traumatic brain injury in adults and children.

AI Analysis | Feedback

AI Analysis | Feedback

AI Analysis | Feedback

Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer

Dr. Rosenwald has served as Fortress Biotech's Chairman, President, and Chief Executive Officer since December 2013 and as a member of its Board of Directors since October 2009. He is recognized as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. From 1991 to 2008, Dr. Rosenwald was the Chairman of Paramount BioCapital, Inc. He is also a co-founder of the healthcare private equity firm Opus Point Partners. Dr. Rosenwald has a history of creating and selling several biotechnological companies. Notably, prior to joining Fortress, he acquired a distressed biotech company during a bear market and subsequently sold it for a 500% profit within months.

David Jin, Chief Financial Officer and Head of Corporate Development

Mr. Jin has been Fortress Biotech's Chief Financial Officer since August 2022 and Head of Corporate Development since May 2020. He also holds positions as Interim Chief Financial Officer and Chief Operating Officer of Avenue Therapeutics, a Fortress partner company, and serves on the Board of Directors of Mustang Bio, another Fortress partner company, and Crystalys Therapeutics. Previously, Mr. Jin was part of the investment team in the Private Equity & Real Assets group at Barings, served as Director of Corporate Development at Sorrento Therapeutics, and was Vice President of Healthcare Investment Banking at FBR & Co. He also worked in the management consulting group at IMS Health (now IQVIA).

Michael S. Weiss, Executive Vice Chairman, Strategic Development

Mr. Weiss has served as Executive Vice Chairman, Strategic Development of Fortress Biotech since February 2014. He is currently the Executive Chairman of the Board of Directors of Mustang Bio, Inc. Mr. Weiss also served as Chairman of the Board of Directors of Checkpoint Therapeutics, Inc. until its acquisition in May 2025. Since December 2011, he has held multiple roles at TG Therapeutics, Inc., where he is currently its Executive Chairman, Chief Executive Officer, and President. In 1999, Mr. Weiss founded Access Oncology, which was acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004, and he remained Chief Executive Officer of Keryx after the merger. He is also a Partner at Opus Point Partners Management LLC.

Samuel Berry, General Counsel and Corporate Secretary

Mr. Berry has served as General Counsel and Corporate Secretary of Fortress Biotech since September 2018, having joined the legal team in June 2016. He also provides internal counsel to most of Fortress' subsidiaries and partner companies. Prior to joining Fortress, Mr. Berry was an associate attorney in the Corporate & Securities group at Mayer Brown LLP, specializing in mergers and acquisitions, licensing, venture capital, and capital markets transactions.

AI Analysis | Feedback

The key risks for Fortress Biotech (FBIO) are:

1. High Risk of Clinical Trial Failure and Regulatory Non-Approval: Fortress Biotech has an extensive pipeline of late-stage, early-stage, and preclinical product candidates across various therapeutic areas. The biopharmaceutical industry faces inherent and significant risks associated with the development of new drugs, including high failure rates in clinical trials and the uncertainty of obtaining regulatory approvals from health authorities. The success of these numerous product candidates is critical for the company's future growth and profitability.
2. Significant Capital Requirements and Funding Risk: Developing and bringing pharmaceutical products through clinical trials to market is an extremely expensive and time-consuming process. Given its broad and largely unapproved pipeline, Fortress Biotech will likely require substantial additional capital to fund its research and development activities, clinical trials, and potential commercialization efforts. There is a risk that the company may not be able to obtain necessary financing on favorable terms, or at all, which could impede its development programs and operations.
3. Intense Competition and Commercialization Challenges: The biopharmaceutical market is highly competitive. Fortress Biotech's existing marketed dermatology products face competition, and any future products that gain approval will enter markets with established treatments and intense competition from larger, more experienced pharmaceutical companies. There is also a risk that, even if approved, pipeline products may not achieve market acceptance or generate sufficient revenue due to various factors including pricing pressure, physician adoption, and reimbursement challenges.

AI Analysis | Feedback

The emergence and development of allogeneic ("off-the-shelf") CAR T-cell therapies by competitors represent a clear emerging threat to Fortress Biotech's pipeline of autologous (patient-specific) CAR T-cell candidates, such as MB-106 for B-cell non-Hodgkin lymphoma and other MB-labeled cell therapies for various cancers. If successfully commercialized, these allogeneic alternatives could offer significant advantages in terms of manufacturing scalability, cost-effectiveness, and faster patient access compared to existing or developing autologous approaches, potentially displacing them in the market.

AI Analysis | Feedback

Addressable Markets for Fortress Biotech's Main Products and Services

• Acne Vulgaris (Ximino, Targadox, Accutane): The global acne vulgaris market size is projected to reach approximately USD 8.74 billion by 2030. Other estimates indicate the global market is expected to reach USD 11.46 billion by 2030. In the seven major markets (7MM), the market size was approximately USD 4.26 billion in 2023, with the United States accounting for about USD 2.95 billion. The 7MM market is further expected to reach USD 10.4 billion by 2035.
• Menkes Disease (CUTX-101): The global Menkes disease market is estimated to be valued at USD 176.3 million in 2025 and is expected to reach USD 279.4 million by 2032. Another report values the global Menkes syndrome market at USD 5.44 million in 2024, projected to reach USD 10.44 million by 2032. In the 7MM, the market size was approximately USD 7.9 million in 2023, with the U.S. contributing around USD 7 million.
• Metastatic Cancers (Cosibelimab): The global metastatic cancer drugs market was valued at USD 67.7 billion in 2022 and is projected to reach USD 136.9 billion by 2032. The global metastatic cancer treatment market is estimated at USD 91.44 billion in 2026, with projections indicating it will reach USD 134.39 billion by 2031. Additionally, the global market for cancer therapeutics, with an emphasis on recurrent and metastatic divisions, was valued at USD 108.1 billion in 2023 and is projected to reach USD 168.0 billion by the end of 2029.
• Amyloid Light Chain Amyloidosis (CAEL-101): The global systemic light chain (AL) amyloidosis market size was valued at USD 2.59 billion in 2025 and is expected to reach USD 3.68 billion by 2033. Another source indicates the global AL Amyloidosis Therapeutics market size was USD 2.19 billion in 2024 and is projected to grow to USD 3.68 billion by 2032. The broader global amyloidosis treatment market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 11.13 billion by 2033.
• Cytomegalovirus (CMV) (Triplex vaccine): The global cytomegalovirus (CMV) treatment market was valued at USD 436.7 million in 2022. More recent estimates project the global cytomegalovirus market size at USD 647.10 million in 2024, expected to reach USD 1070.95 million by 2032. Another report indicates the global cytomegalovirus treatment market is poised for steady expansion, with an estimated value of USD 2.3 billion in 2024, projected to reach around USD 3.6 billion by 2030.
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (MB-102): The global blastic plasmacytoid dendritic cell neoplasm market size was estimated at USD 127.65 million in 2023 and is projected to grow to USD 214.27 million by 2030. The market size was valued at USD 136.72 million in 2024 and is projected to grow to USD 282.81 million by 2034.
• Glioblastoma (GBM) (MB-101, MB-103): The global glioblastoma multiforme treatment market was valued at USD 3.6 billion in 2024 and is expected to grow to USD 8.3 billion in 2034. Other projections show the global market size at USD 4.04 billion in 2025, reaching USD 7.87 billion by 2033. The market size was also reported as USD 2.78 billion in 2024, expected to reach around USD 5.68 billion by 2033.
• Multiple Myeloma (MB-104): The global multiple myeloma market size stood at USD 31.00 billion in 2026 and is projected to reach USD 49.79 billion by 2034. Another report estimates the global market size at USD 27.75 billion in 2024, projected to grow to USD 49.89 billion by 2034. In 2023, the total multiple myeloma market size in the 7MM was approximately USD 21.3 billion, with the United States contributing nearly USD 14.3 billion.
• Prostate Cancers (MB-105): The global prostate cancer market size reached USD 12 billion in 2022 and is projected to surpass approximately USD 27.51 billion by 2032. The prostate cancer market size in 2026 is estimated at USD 25.73 billion, with projections showing USD 38.33 billion by 2031. Another assessment puts the global prostate cancer treatment market size at USD 16.05 billion in 2025, projected to reach around USD 36.90 billion by 2035.
• Pancreatic Cancers (MB-105): The global pancreatic cancer treatment market size was estimated at USD 2.92 billion in 2024 and is projected to reach USD 5.84 billion by 2030. Other estimates suggest the pancreatic cancer market size was valued at USD 3.28 billion in 2025 and is likely to cross USD 12.05 billion by 2035. The global pancreatic cancer industry is expected to increase from USD 2.65 billion in 2024 to USD 9.57 billion by 2034.

AI Analysis | Feedback

Fortress Biotech (FBIO) is poised for future revenue growth over the next 2-3 years, driven primarily by the commercialization and expansion of its key pharmaceutical products, as well as anticipated milestone and royalty payments from its diverse pipeline.

1. Accelerated Sales Growth of Emrosi™: Emrosi™, an oral treatment for rosacea launched by Fortress' subsidiary Journey Medical, is a significant driver of current and expected future revenue growth. The product has demonstrated strong sequential revenue and prescription growth, with management anticipating peak annual net sales exceeding $200 million in the U.S. and $300 million globally. Continued expansion of the prescriber base and increasing payer coverage are expected to fuel this growth.
2. Royalties and Milestone Payments from ZYCUBO® (formerly CUTX-101): ZYCUBO®, developed by Cyprium Therapeutics (a majority-owned subsidiary of Fortress Biotech), recently received FDA approval in January 2026 for the treatment of Menkes disease in pediatric patients. Fortress is eligible to receive tiered royalties on net sales and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics, which is responsible for its commercialization. Additionally, the FDA approval included a Rare Pediatric Disease Priority Review Voucher (PRV), which Cyprium retains and can sell for substantial revenue, further contributing to Fortress' financial inflows.
3. Royalties from UNLOXCYT™ (cosibelimab-ipdl): Following the acquisition of Checkpoint Therapeutics (a Fortress-founded company) by Sun Pharma in 2025, Fortress Biotech is eligible to receive a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl), an FDA-approved treatment for metastatic cancers. These royalty payments, along with potential contingent value right (CVR) payments, are expected to provide a stable and growing revenue stream.
4. Future Royalties from Dotinurad: Urica Therapeutics, a company founded by Fortress, sold dotinurad for gout treatment to Crystalys Therapeutics. Fortress retains equity in Crystalys and is eligible for a 3% royalty on future net sales of dotinurad. With Crystalys funding global Phase 3 trials for dotinurad, and the drug already approved in Asia, the progression of its clinical development and potential future approvals are expected to contribute to Fortress' revenue through royalties within the 2-3 year timeframe and beyond.

AI Analysis | Feedback

Share Repurchases

• In January 2022, Fortress Biotech announced an authorized program of up to $5 million for the repurchase of its Series A Cumulative Redeemable Perpetual Preferred Stock.

Share Issuance

• Throughout 2024, Fortress Biotech and its subsidiaries raised approximately $21.1 million through equity offerings.
• In February 2023, the company completed a Follow-on Equity Offering, raising $13.9 million.
• The number of outstanding shares increased significantly, from 7.49 million at the end of 2023 to 19.69 million at the end of 2024 (a 162.68% change), and further to 27.24 million by the end of 2025 (a 38.32% change).

Inbound Investments

• In February 2026, Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, agreed to sell its Rare Pediatric Disease Priority Review Voucher for $205 million, with Fortress expecting to receive at least $100 million from Cyprium through dividends and intercompany arrangements.
• Fortress Biotech received approximately $28 million upfront, with potential for an additional $4.8 million contingent value right (CVR) payment and 2.5% royalties on future net sales, from Sun Pharma's acquisition of its subsidiary Checkpoint Therapeutics.
• In July 2024, the company entered into a $50 million term loan agreement with Oaktree Capital Management, replacing a previous $50 million loan.

Outbound Investments

• Fortress Biotech retains a minority position in Crystalys Therapeutics and is eligible for 3% royalty payments on future net sales of Dotinurad, a drug originally developed by its majority-owned subsidiary Urica Therapeutics, which sold Dotinurad to Crystalys Therapeutics in 2024.
• Fortress can receive up to $125 million from AstraZeneca after reaching certain R&D and commercial milestones related to CAEL-101 (anselamimab), a monoclonal antibody for AL amyloidosis, following AstraZeneca's acquisition of Fortress' former subsidiary, Caelum, in 2021.

Capital Expenditures

• Fortress Biotech's average capital expenditure over the past five years has been approximately $2.88 million.
• Reported capital expenditures were $2.68 million in 2023, $2.88 million in 2022, and $1.11 million in 2024.
• The trailing twelve months (TTM) capital expenditure as of September 30, 2025, was $588.14K.